Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage

Documenti analoghi

• Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer
  di: Jacob Hanna, et al.
  Pubblicazione: (2026)
• Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
  di: Arjun Pon Avudaiappan, et al.
  Pubblicazione: (2024)
• Understanding oncological and sexual function outcomes with gynaecological organ preserving cystectomy in women with bladder cancer; a systematic review
  di: Rebecca Martin, et al.
  Pubblicazione: (2025)
• Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study
  di: Chase Peng Yun Ng, et al.
  Pubblicazione: (2025)
• Patient experience of bladder cancer: A data linkage study
  di: Snehadhar Shah, et al.
  Pubblicazione: (2024)